---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000132"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:06:08.616678+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioMarin to cut ~225 jobs, incur $30-35M in severance costs by end of 2024

## Summary
- Workforce reduction of ~225 employees committed on Aug 23, 2024, in organizational redesign.
- Estimated pre-tax charges of $30-35M for severance and termination benefits, mostly in H2 2024.
- Plan follows updated ROCTAVIAN strategy and discontinuation of BMN 293 development announced Aug 5, 2024.
- Notifications completed by Aug 28, 2024; reductions expected substantially complete by end of 2024.

## SEC filing metadata
- accession: 0001048477-24-000132
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000132/0001048477-24-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000132/bmrn-20240823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000132
- JSON: https://secwatch.observer/filing/0001048477-24-000132.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.